List of Excipients in Branded Drug CERDELGA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genzyme Corporation	CERDELGA	eliglustat	58468-0220	CELLULOSE, MICROCRYSTALLINE
Genzyme Corporation	CERDELGA	eliglustat	58468-0220	FD&C BLUE NO. 2
Genzyme Corporation	CERDELGA	eliglustat	58468-0220	FERRIC OXIDE YELLOW
Genzyme Corporation	CERDELGA	eliglustat	58468-0220	GELATIN
Genzyme Corporation	CERDELGA	eliglustat	58468-0220	GLYCERYL DIBEHENATE
Genzyme Corporation	CERDELGA	eliglustat	58468-0220	HYPROMELLOSE
Genzyme Corporation	CERDELGA	eliglustat	58468-0220	LACTOSE MONOHYDRATE

Last updated: August 11, 2026

Cerdelga’s commercial value is concentrated in a technically simple but clinically sensitive oral capsule. The active ingredient, eliglustat tartrate, is a CYP2D6- and CYP3A-sensitive substrate-reduction therapy for adults with Gaucher disease type 1. The strongest excipient opportunities are lactose-free reformulation, capsule-shell differentiation, modified-release development, and generic or 505(b)(2) products that improve administration while preserving eliglustat exposure. The main constraint is pharmacokinetic control: excipient changes cannot materially alter dissolution, absorption, or dose exposure across CYP2D6 metabolizer groups.

Cerdelga Excipient Strategy and Commercial Opportunities

What is Cerdelga and how does its formulation work?

Cerdelga is an oral capsule containing eliglustat tartrate, equivalent to 84 mg of eliglustat. Sanofi markets Cerdelga for the long-term treatment of adults with Gaucher disease type 1 who are CYP2D6 extensive, intermediate, or poor metabolizers, subject to the product’s dosing restrictions. Ultra-rapid metabolizers are generally not appropriate candidates because of reduced exposure risk [1].

Cerdelga reduces glucosylceramide synthesis through substrate reduction. Its clinical performance depends on systemic eliglustat exposure, which is strongly affected by CYP2D6 genotype and by concomitant CYP2D6 or CYP3A inhibitors and inducers [1].

The dosage form is an immediate-release hard gelatin capsule. Its excipient system is designed for conventional oral disintegration and dissolution rather than sustained release or site-specific delivery.

Cerdelga formulation profile

Attribute	Cerdelga characteristic
Active ingredient	Eliglustat tartrate
Strength	84 mg eliglustat equivalent per capsule
Dosage form	Immediate-release hard capsule
Route	Oral
Indication	Gaucher disease type 1
Dosing	Usually once or twice daily, based on CYP2D6 metabolizer status and interacting medicines
Manufacturer	Sanofi, through its Genzyme rare-disease business
FDA approval	August 19, 2014
Pharmacokinetic sensitivity	High; CYP2D6 genotype and CYP3A/CYP2D6 interactions are clinically relevant
Regulatory category	Small-molecule prescription drug, not a biologic

What excipients are used in Cerdelga capsules?

The U.S. prescribing information identifies lactose monohydrate, microcrystalline cellulose, crospovidone, talc, and magnesium stearate in the capsule fill. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide, and black iron oxide. Printing components include shellac-based and iron-oxide colorants [1].

The formulation has a conventional architecture:

1. Lactose monohydrate acts as a soluble diluent.
2. Microcrystalline cellulose provides bulk and compressibility within the capsule fill.
3. Crospovidone promotes rapid disintegration.
4. Talc supports powder processing and flow.
5. Magnesium stearate reduces tooling and capsule-filling friction.
6. Gelatin and mineral pigments provide the capsule shell and color coding.

The principal excipient issue is lactose exposure. Lactose is widely accepted in pharmaceutical products, but it can create commercial friction for patients with lactose intolerance, dietary restrictions, or preference for lactose-free medicines. A lactose-free version could support product differentiation, although the clinical and commercial value would depend on regional labeling requirements and patient demand.

Which excipient changes have the strongest commercial potential?

1. Lactose-free immediate-release capsule

The most practical lifecycle strategy is replacing lactose monohydrate with a direct-compression or capsule-compatible alternative such as mannitol, anhydrous dibasic calcium phosphate, spray-dried cellulose systems, or a co-processed filler.

The replacement must preserve:

• Capsule fill weight
• Powder flow
• Content uniformity
• Disintegration time
• Dissolution profile
• Moisture stability
• Eliglustat assay and degradation profile
• Bioequivalence

Mannitol is commercially attractive because it is lactose-free, chemically stable, and familiar to patients and regulators. Its higher cost and different compaction and flow behavior can require changes to particle-size distribution, lubricant level, or blending conditions.

A co-processed excipient system could reduce development time by combining flow, dilution, and disintegration functions. The tradeoff is higher supplier dependence and potential patent or know-how constraints around the co-processed material.

2. Hypoallergenic or vegetarian capsule shell

The current hard gelatin shell creates an opportunity for a hydroxypropyl methylcellulose or pullulan capsule. A vegetarian capsule could expand use among patients who avoid animal-derived gelatin and simplify positioning in markets with religious or dietary restrictions.

The key technical risks are moisture transfer and shell performance. HPMC shells have different water activity, brittleness, oxygen permeability, and dissolution behavior from gelatin. Those differences matter for a compound whose clinical dosing depends on predictable exposure.

A shell conversion would require comparative stability, dissolution, extractables and leachables assessment, and likely human bioequivalence work if the change affects in vivo performance. It may be commercially valuable in Europe, the Middle East, Asia, and institutional procurement channels, but it is less likely to support a premium by itself in the United States.

3. Sprinkle or alternative oral administration

A capsule that can be opened and sprinkled onto soft food could address swallowing difficulty, pediatric transition, and caregiver administration. This is a higher-value opportunity than a simple color or shell change, but it carries substantial development risk.

Eliglustat is approved for adults, so pediatric demand is not the primary commercial driver. The opportunity would instead involve adults with dysphagia, older patients, and patients with treatment-related administration barriers.

A sprinkle product would need data on:

• Stability after capsule opening
• Uniformity of dose recovered from food
• Food compatibility
• Adsorption to utensils or containers
• Taste and odor
• Protection from moisture
• Exposure relative to the intact capsule

A multiparticulate formulation could also improve dose flexibility. That strategy would be more difficult because it could alter dissolution and absorption and would require a robust control strategy for bead size, coating thickness, and dose uniformity.

4. Modified-release formulation

A delayed-release or extended-release product is technically possible but commercially less compelling. Cerdelga already has a low-frequency oral regimen for some patients, and the product’s main dosing burden arises from pharmacogenomics and drug interactions rather than short half-life alone.

Modified release could theoretically:

• Reduce peak-to-trough fluctuation
• Support once-daily use across a broader patient segment
• Improve adherence
• Limit gastrointestinal intolerance

The main barrier is exposure control. Eliglustat has clinically significant interaction restrictions, and a modified-release system would not eliminate CYP2D6 or CYP3A liability. A new-release profile could also create a new safety issue if absorption becomes less predictable in poor metabolizers or in patients receiving inhibitors.

How does Cerdelga’s excipient strategy affect generic entry?

Generic eliglustat products are likely to target the immediate-release capsule pathway because the dosage form is established and the active ingredient is a small molecule. The technical challenge is not basic capsule manufacture. It is matching the reference product’s dissolution and systemic exposure while complying with pharmacogenomic dosing requirements.

Generic development barriers

Barrier	Commercial effect
CYP2D6-dependent exposure	Requires careful subject selection and pharmacokinetic analysis
CYP3A and CYP2D6 interactions	Increases clinical and labeling complexity
Low patient population	Limits achievable volume and may discourage multiple entrants
Rare-disease distribution	Requires specialist sales and reimbursement infrastructure
Capsule excipient differences	Can affect dissolution, stability, and bioequivalence
Reference-product intellectual property	May delay launch even after ordinary exclusivity expires
Prescriber familiarity with pharmacogenomic dosing	Raises education and substitution-management costs

A generic manufacturer can use a different excipient system if the product meets applicable quality and bioequivalence requirements. The commercial opportunity is strongest for suppliers that can provide a complete lactose-free capsule platform rather than a single replacement excipient.

For an innovator or specialty manufacturer, the more defensible strategy is a differentiated dosage form supported by clinical convenience, not a purely cosmetic excipient change. A lactose-free or vegetarian capsule may improve marketability but may not justify a substantial price premium without evidence of adherence or patient benefit.

What regulatory exclusivity and patent issues affect Cerdelga?

Cerdelga received U.S. approval in 2014 and benefited from orphan-drug exclusivity for Gaucher disease type 1. The seven-year U.S. orphan exclusivity period would have run from approval to August 2021, subject to the scope of the approved indication and any applicable regulatory events [1,2].

The five-year new chemical entity exclusivity period would have provided a shorter initial barrier, ending before the orphan period. Regulatory exclusivity does not determine the full generic-entry date because patent claims, pediatric exclusivity, litigation, and court decisions can extend or alter the practical launch timeline.

Orange Book and patent considerations

Cerdelga is an FDA-listed small-molecule product, so its U.S. entry analysis requires review of:

• Current Orange Book patent listings
• Active ingredient and composition claims
• Formulation and dosage-form claims
• Method-of-use claims tied to Gaucher disease treatment
• Pharmacogenomic dosing claims
• Pediatric exclusivity, if any
• Paragraph IV certifications
• Any 30-month stay or settlement agreement
• Patent-term adjustment or patent-term extension

The most relevant patent exposure is likely to concern eliglustat composition, pharmaceutical compositions, therapeutic use, and dosing in CYP2D6-defined patient groups. Excipient patents are less likely to block ordinary generic entry unless they claim a specific formulation architecture or a commercially necessary stability or dissolution profile.

A manufacturer pursuing a lactose-free product could use a different formulation and make a non-infringement position stronger, but the product would still face active-ingredient and method-of-use patents. Excipient substitution is therefore a design-around tool, not a complete freedom-to-operate strategy.

What formulation patents could protect a Cerdelga lifecycle product?

A lifecycle formulation would be most defensible if it claims a measurable technical advantage. Potential claim categories include:

Lactose-free formulation claims

These could cover:

• Eliglustat with a defined mannitol or cellulose-based filler
• Specified crospovidone and lubricant ranges
• Dissolution thresholds at defined time points
• Moisture limits
• Stability after accelerated storage

A simple “lactose-free” limitation may be commercially useful but can be vulnerable if many conventional alternatives are available.

Capsule-shell claims

Claims could focus on:

• HPMC or pullulan shell composition
• Water-content range
• Colorant system
• Oxygen or moisture barrier
• Compatibility with eliglustat fill material

Shell claims may be easier to design around than active-ingredient claims.

Pharmacogenomic dosing claims

Method-of-use claims could cover administering eliglustat based on CYP2D6 phenotype or genotype. Such claims have commercial relevance because the product label incorporates metabolizer-specific dosing. Their enforceability depends on claim language, divided-infringement issues, prescriber conduct, and the scope of applicable U.S. patent law.

Combination and interaction-management claims

A future product could target coadministration rules or dosing adjustments in patients receiving selected CYP2D6 or CYP3A inhibitors. These claims would have practical value but face enablement and obviousness challenges if they merely restate known pharmacokinetic relationships.

Which companies have commercial opportunities around Cerdelga excipients?

The opportunity set includes excipient producers, capsule suppliers, contract development and manufacturing organizations, and specialty generic companies.

Excipient suppliers

Potential suppliers can compete on:

• Low-moisture lactose replacements
• Co-processed fillers
• Direct-fill mannitol systems
• High-functionality microcrystalline cellulose
• Fast-disintegrating capsule blends
• HPMC and pullulan shells
• Low-peroxide excipients
• Pharmaceutical-grade colorants

Supplier differentiation will depend on regulatory documentation, global compendial coverage, change-control discipline, and supply continuity. For a rare-disease product, technical support and small-batch capability may be more important than commodity pricing.

CDMOs

CDMOs can package a full development offer covering:

• Formulation screening
• Capsule-fill optimization
• Comparative dissolution
• Stability studies
• Clinical bioequivalence
• Scale-up
• Commercial packaging
• Regulatory support

The best-positioned CDMOs will have experience with highly variable or genotype-sensitive PK products. Standard generic capsule capability alone is less valuable.

Specialty generic manufacturers

A generic company could pursue a conventional capsule with a lower-cost excipient system, while a specialty manufacturer could target:

• Lactose-free Cerdelga-equivalent product
• Vegetarian capsule
• Patient-friendly pack configuration
• Regional product for markets with limited access
• Authorized generic or licensing arrangement
• 505(b)(2) product with administration or adherence claims

How strong is the commercial opportunity?

The market is attractive on a value-per-patient basis but constrained by disease prevalence. Gaucher disease type 1 is a rare, chronic condition managed through specialist channels. The addressable population is therefore smaller than for common metabolic disorders, but treatment duration can be long and switching costs can be high.

Revenue exposure

Cerdelga revenue is exposed to four principal risks:

1. Generic or authorized-generic entry after regulatory and patent barriers fall.
2. Substitution by enzyme replacement therapy, including home-infusion or extended-interval products.
3. Reimbursement pressure in rare-disease formularies.
4. Treatment switching driven by tolerability, drug interactions, or patient preference.

Excipient reformulation can protect share and support lifecycle management, but it is unlikely to offset a major loss of exclusivity by itself. The greatest commercial value comes from combining formulation differentiation with manufacturing control, regulatory exclusivity, and a patient-service model.

How does Cerdelga compare with competing Gaucher disease treatments?

Product category	Primary administration	Excipient opportunity	Competitive implication
Cerdelga	Oral capsule	Lactose-free, vegetarian shell, sprinkle, modified release	Avoids infusion but has CYP2D6 and CYP3A constraints
Enzyme replacement therapy	Intravenous infusion	Limited patient-facing excipient differentiation	Competes on established efficacy and clinical familiarity
Other substrate-reduction therapies	Oral solid dosage form	Taste masking, capsule or tablet engineering, adherence packaging	Compete on interaction profile and dosing convenience
Emerging oral therapies	Oral tablet or capsule	Solubility enhancement, controlled release, food-effect management	Could pressure Cerdelga if they offer broader metabolizer coverage

Cerdelga’s oral route is its principal commercial advantage. Its pharmacogenomic dosing and interaction profile are the main weaknesses. An improved excipient system cannot remove those liabilities unless the reformulation materially changes pharmacokinetics, which would require a substantially larger development program.

What manufacturing and intellectual-property barriers matter most?

The manufacturing process is comparatively accessible because Cerdelga is an oral hard capsule, not a sterile biologic. The more important barriers are:

• Consistent low-dose blend uniformity relative to total capsule mass
• Protection from moisture and oxidation
• Control of polymorphic or solid-state behavior
• Reproducible dissolution
• Reliable capsule filling
• Global supply of pharmaceutical-grade excipients
• Clinical bioequivalence across relevant metabolizer groups
• Freedom to operate around active-ingredient and use patents

A manufacturer should avoid excipient changes that increase dissolution variability. Lubricant overuse, excessive hydrophobicity, poor powder segregation control, and shell moisture mismatch could produce a nominally equivalent product with materially different exposure.

Key Takeaways

• Cerdelga is an immediate-release eliglustat tartrate capsule with a conventional excipient system.
• Lactose-free reformulation is the clearest near-term excipient opportunity.
• HPMC or pullulan shells could support vegetarian and regional-market positioning.
• Sprinkle and modified-release products offer higher differentiation but carry greater PK and regulatory risk.
• CYP2D6 genotype and CYP3A/CYP2D6 drug interactions make bioequivalence more sensitive than ordinary capsule development.
• Excipient substitution may support design-around work but does not eliminate active-ingredient or method-of-use patent risk.
• The most attractive commercial model combines a differentiated formulation with specialty-generic distribution, adherence support, and regulatory strategy.
• Cerdelga’s oral convenience remains its strongest competitive asset; pharmacokinetic interaction management remains its principal limitation.

FAQs

Can Cerdelga be reformulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose systems, dibasic calcium phosphate, or a co-processed excipient. The reformulated capsule would need comparative quality, stability, dissolution, and bioequivalence support.

Would a vegetarian capsule improve Cerdelga market access?

Potentially. An HPMC or pullulan shell could address dietary and religious restrictions. The commercial effect would be strongest in markets where gelatin avoidance affects prescribing, procurement, or patient acceptance.

Is an excipient patent enough to block a generic Cerdelga product?

Usually not by itself. A generic product could use a non-infringing excipient system if it meets regulatory requirements. Active-ingredient, formulation, and method-of-use patents may remain more important barriers.

Could a Cerdelga sprinkle formulation support pediatric use?

It could support future pediatric development, but the current approved indication is for adults. A sprinkle product would require administration, stability, dose-uniformity, palatability, and clinical-development evidence.

Does modified release solve Cerdelga’s CYP2D6 interaction problem?

No. Modified release may change exposure timing, but it does not inherently remove CYP2D6 or CYP3A metabolism, genotype-dependent dosing, or contraindicated drug interactions.

References

1. U.S. Food and Drug Administration. (2024). Cerdelga (eliglustat tartrate) prescribing information.
2. U.S. Food and Drug Administration. (2024). Drugs@FDA: Cerdelga application and regulatory history.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
4. European Medicines Agency. (2015). Cerdelga: EPAR product information.
5. Sanofi. (2024). Annual report and regulated information.